Keep your finger on the pulse of breakthroughs
Our team and providers are operating at the forefront of regenerative research, clinical practice, and care.
Search our databaseOther news
Japan Provides Conditional Approval for Stem Cell Repair for the Heart and Brain
Japan conditionally approves stem cell treatments for Parkinson’s and heart failure. Clinical trials show significant functional recovery, shifting from managing symptoms to restoring health.
Un-Break My Heart: MSC Therapy and the Future of Heart Disease Treatment
MSC Therapy for Heart Disease: Regenerative approach with Mesenchymal Stem Cells to restore cardiac function. Studies like DREAM-HF show a 58% reduced risk of heart attack, moving beyond symptom management.
New Hope for Heart Repair: Stem Cell Exosomes and Smart Delivery Systems
Your body's repair cells send out tiny "healing packages" that can help fix a heart after a heart attack. New medical studies show that using special patches to keep these packages in place helps the heart heal much faster.
Why freezing your young stem cells matters today
Why freezing your young stem cells matters today. Bank your young Mesenchymal Stem Cells (MSCs) today to secure a high-potency, genetically-matched 'medical reserve' for your future. Research shows that younger MSCs offer enhanced healing, boost cognitive function, and are linked to extended healthspan, providing an ideal resource for future regenerative therapies while eliminating the risk of immune rejection.
BioCardia’s CardiAMP HF II Phase 3 Trial: First Patient Enrolled at University of Wisconsin
BioCardia announced that the University of Wisconsin School of Medicine and Public Health enrolled its first patient in the Phase 3 CardiAMP HF II trial. This trial is testing CardiAMP, an autologous (patient’s own) bone marrow cell therapy, in people with ischemic heart failure with reduced ejection fraction (HFrEF) who still have signs of heart stress despite optimized medical care.
Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)
AIMS: Regenerative treatment with mesenchymal stromal cells (MSCs) has been promising in patients with ischaemic heart failure but needs confirmation in larger randomized trials. We aimed to study effects of intra-myocardial autologous bone marrow-derived MSC treatment in patients with severe ischaemic heart failure. __METHODS AND RESULTS__ The MSC-HF trial is a randomized, double-blind, placebo-controlled trial. Patients were randomized 2 : 1 to intra-myocardial injections of MSC or placebo, respectively. The primary endpoint was change in left ventricular end-systolic volume (LVESV), measured by magnetic resonance imaging or computed tomography at 6 months follow-up. Sixty patients aged 30-80 years with severe ischaemic heart failure, New York Heart Association (NYHA) classes II-III, left ventricular ejection fraction (LVEF) <45% and no further treatment options were randomized. Fifty-five patients completed the 6-month follow-up (37 MSCs vs. 18 placebo). At 6 months, LVESV was reduced in the MSC group: -7.6 (95% CI -11.8 to -3.4) mL (P = 0.001), and increased in the placebo group: 5.4 (95% CI -0.4 to 11.2) mL (P = 0.07). The difference between groups was 13.0 (95% CI 5.9-20.1) mL (P = 0.001). Compared with placebo, there were also significant improvements in LVEF of 6.2% (P<0.0001), stroke volume of 18.4 mL (P < 0.0001), and myocardial mass of 5.7 g (P = 0.001). No differences were found in NYHA class, 6-min walking test and Kansas City cardiomyopathy questionnaire. No side effects were identified. __CONCLUSION__ Intra-myocardial injections of autologous culture expanded MSCs were safe and improved myocardial function in patients with severe ischaemic heart failure.
